Turning a pathogen protein into a therapeutic tool for sepsis.
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380
Informations de publication
Date de publication:
11 01 2021
11 01 2021
Historique:
received:
24
10
2020
accepted:
27
10
2020
pubmed:
18
12
2020
medline:
6
10
2022
entrez:
17
12
2020
Statut:
ppublish
Résumé
Sepsis causes unacceptably high amounts of deaths worldwide. It is a huge unmet medical need, and new therapeutic interventions for sepsis and septic shock are urgently needed. By studying the mechanism by which a bacterial protein undermines the inflammatory function of macrophages, Kim et al, in the last issue of EMBO Molecular Medicine, have developed a new therapeutic protein drug, which appears to have very promising protective activities in a well-validated and aggressive polymicrobial sepsis model in mice. The chimeric protein is thought to limit macrophage inflammation while activating phagocytosis, and so, it hits two macrophage pathways at once.
Identifiants
pubmed: 33332738
doi: 10.15252/emmm.202013589
pmc: PMC7799353
doi:
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13589Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2020 The Authors. Published under the terms of the CC BY 4.0 license.
Références
EMBO Mol Med. 2018 Aug;10(8):
pubmed: 29976786
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
Immunology. 2010 May;130(1):34-45
pubmed: 20201990
Nat Rev Nephrol. 2018 Feb;14(2):121-137
pubmed: 29225343
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Trends Microbiol. 2011 Apr;19(4):198-208
pubmed: 21296575
EMBO Mol Med. 2020 Dec 7;12(12):e12497
pubmed: 33258196
N Engl J Med. 2017 Aug 3;377(5):414-417
pubmed: 28658587
Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):13353-13358
pubmed: 30530654